About Relmada Therapeutics
Relmada Therapeutics (NASDAQ:RLMD) is a clinical-stage biotech company focused on developing novel therapies for the treatment of central nervous system (CNS) diseases, particularly those related to depression and other psychiatric disorders. Their portfolio includes multiple innovative projects aiming to address the unmet medical needs in mental health and pain management. One of their flagship products, REL-1017, is an NMDA receptor antagonist currently in advanced clinical trials for major depressive disorder, showcasing their commitment to pioneering treatments that can improve patient outcomes. With a clear objective to revolutionize the landscape of psychiatric and neurological care, Relmada Therapeutics is dedicated to advancing its research and development efforts to bring new, effective therapeutic options to market.
Snapshot
Operations
Produtos e/ou serviços de Relmada Therapeutics
- Relmioram, a novel NMDA receptor antagonist for major depressive disorder, in Phase 3 clinical trials.
- Development of therapies targeting central nervous system (CNS) diseases, including chronic pain.
- Exploration of novel formulations and delivery methods for enhanced drug efficacy and patient compliance.
- Investigations into potential treatments for neuropathic pain.
equipe executiva do Relmada Therapeutics
- Dr. Sergio Traversa M.B.A., Pharm.D.CEO & Director
- Mr. Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer
- Mr. Paul E. Kelly M.B.A.COO & Director
- Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer
- Ms. Gina DiGuglielmoVP & Head of Clinical Operations
- Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A.Chief Medical Officer of Urology
- Dr. Andrew CutlerSenior Clinical Development Advisor
- Dr. Richard M. Mangano Ph.D.Consultant